Both medications are FDA-approved for chronic weight management and represent the most clinically significant advancement in non-surgical weight loss in decades
Possible monitoring points include injection site reactions, swelling, joint discomfort, muscle aches, numbness or tingling, blood sugar changes, or fluid retention
All patients must have had continuous medical and pharmacy enrollment 6 months prior to the index date (baseline period) and 12 months after the index date (follow-up period
Parkinsons Disease 2021:1 Song Q, Peng S, Zhu X (2021) Baicalein protects against MPP+/MPTP-induced neurotoxicity by ameliorating oxidative stress in SH-SY5Y cells and mouse model of Parkinsons disease
Premium-grade research peptide.
One recent study found that people using semaglutide or a related drug for weight loss had an increased risk of serious gastrointestinal conditions, including inflammation of the pancreas and bowel blockages, compared with people using a different type of weight-loss drug
